On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.Market news: Hungary and Bulgaria find solutions for Russian natural gas transportation.On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.
Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.Market News: Austria provides 1,000 euros to Syrian refugees to help them return home.Market News: Turkish anti-monopoly agency fined Google $75 million for advertising technology investigation.
BYD Lian Yubo: It is estimated that BYD will sell 4.25 million vehicles in the whole year. On December 13th, BYD's chief scientist Lian Yubo said: "Up to now, BYD has sold more than 10 million new energy vehicles. By the end of this month, we can probably achieve the annual sales of 4.25 million vehicles. " He also mentioned: "There are still some challenges in industrial development. For example, the overall anti-risk ability of our industrial chain needs to be improved, and there are still breakthroughs in chips, operating technologies, industrial software and nuclear materials. We still need to strengthen research and achieve complete autonomy and controllability."Bei Ya raised the Amazon target price from $220.00 to $260.00.Guoyuan Securities: A special dividend plan was drawn up and announced by Guoyuan Securities. On December 13, 2024, the company held the 20th meeting of the 10th Board of Directors and the 11th meeting of the 10th Board of Supervisors, at which the Proposal on Special Dividend Plan was reviewed and approved. As of September 30, 2024, the accumulated undistributed profit of the company was 7.743 billion yuan, and the accumulated distributable profit of the parent company was 5.262 billion yuan. In order to enhance the investor's sense of gain and improve the investor's return level, the company has drawn up a special dividend plan: based on the existing total share capital of 4.364 billion shares, a cash dividend of 0.60 yuan will be distributed to all shareholders for every 10 shares, and a total cash dividend of 262 million yuan will be distributed. No bonus shares will be distributed, and capital will not be increased from the provident fund.
Strategy guide
Strategy guide 12-14
Strategy guide
12-14